ABSTRACT: Cancer represents a multifaceted global health burden shaped by diverse genetic, epigenetic, and environmental factors. The GLOBOCAN 2022 data emphasize the growing incidence and regional variation of cancers such as breast, lung, colorectal, and oral malignancies. Underlying this burden are complex oncogenic signaling pathways—including Wnt/β-catenin, Notch, Hedgehog, PI3K/AKT/mTOR, and JAK/STAT—that regulate cell proliferation, apoptosis, and metastasis. While therapeutic interventions targeting these pathways have shown promise, durable clinical outcomes remain limited due to pathway redundancy, crosstalk, and tumor heterogeneity. This review systematically explores these signaling networks, detailing current and investigational therapeutic targets and the clinical progress of pathway-specific inhibitors. We identify critical gaps in translating molecular insights into personalized therapies and emphasize the need for integrated, multi-targeted approaches. By synthesizing recent advances in molecular oncology and emerging therapeutic strategies, this work offers a forward-looking perspective on overcoming current challenges and optimizing cancer treatment paradigms.
Gera et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: